Cancer mRNA vaccines: clinical application progress and challenges

Area of Science:

• Oncology
• Immunology
• Vaccine Technology

Background:

• Messenger RNA (mRNA) vaccines have demonstrated significant potential in immunotherapy, accelerated by their success during the COVID-19 pandemic.
• The established efficacy and safety profile of mRNA vaccines have spurred exploration into their application for cancer treatment.
• Preclinical and clinical data suggest substantial applicability of mRNA technology in oncology.

Purpose of the Study:

• To review optimization strategies for mRNA cancer vaccines in preclinical research.
• To summarize the progress and challenges of mRNA cancer vaccine clinical trials.
• To analyze delivery vehicles, administration methods, and applications across various cancer types.

Main Methods:

• Comprehensive literature review of preclinical studies and human clinical trials on mRNA cancer vaccines.
• Analysis of vaccine design factors, including antigen selection, stability, and delivery systems.
• Evaluation of safety, tolerability, and immune response data from clinical trials.

Main Results:

• mRNA vaccines effectively induce specific anti-tumor immune responses.
• Clinical trials indicate favorable safety and tolerability profiles for mRNA cancer vaccines.
• Personalized neoantigen vaccines represent a promising direction for future cancer immunotherapy.

Conclusions:

• mRNA vaccines are a viable and advancing therapeutic strategy for cancer treatment.
• Addressing challenges in antigen selection, stability, and resistance is crucial for further development.
• Continued research into personalized mRNA vaccines holds significant potential for improving cancer immunotherapy outcomes.